Telescope Innovations Corp. (TELIF)
| Previous Close | 0.0000 |
| Open | 0.3520 |
| Bid | 0.3040 x 0 |
| Ask | 0.3137 x 0 |
| Day's Range | 0.3520 - 0.3520 |
| 52 Week Range | 0.1350 - 0.5557 |
| Volume | |
| Avg. Volume | 12,403 |
| Market Cap | 16.786M |
| Beta (5Y Monthly) | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Dec 19, 2024 - Dec 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileTelescope Innovations and Altillion Inc. Showcase Proprietary, Simplified Production of Battery-Quality Lithium Carbonate from Brines
Telescope's proprietary ReCRFT process produces >99.5% pure lithium carbonate from Altillion's brine concentrates Vancouver, British Columbia--(Newsfile Corp. - September 17, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope Innovations" or the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and chemical industries, announces the successful outcome of a research engagement with Altillion, Inc. ("Altillion") an innovator
NewsfileTelescope Innovations and Standard Lithium Demonstrate Low-Temperature, High-Purity Production of Lithium Sulfide for Solid-State Batteries
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope Innovations" or the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and chemical industries, announces the successful outcome of a research collaboration with Standard Lithium Ltd. (TSXV: SLI) (NYSE American: SLI) ("Standard Lithium").Over the past year, Telescope Innovations and Standard Lithium have worked toget
NewsfileTelescope Innovations and Pfizer Sign Master Collaborative Research Agreement
Funding from and collaboration with Pfizer could facilitate Telescope's growth and R&D advancement Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the execution of a master collaborative research agreement (the "Agreement") with Pfizer Inc. ("Pfizer"). Under the multi-
